Abstract: A process for preparing and purifying a compound of Formula I is provided: thereof, wherein the subscript m is an integer of from 0 to 3; each Ra is independently selected from the group consisting of (C3-C8)cycloalkyl, (C1-C4)haloalkyl, halogen, —OH, —OR1, —SH, —SR1, —S(O)R1, —S(O)2R1, —SO2NH2, —C(O)NH2, —C(O)NHR1, —C(O)N(R1)2, —C(O)R1, —C(O)H, —CO2H, —CO2R1, —NO2, —NH2, —NHR1, —N(R1)2, wherein each R1 is independently (C1-C8)alkyl; L is a linking group selected from the group consisting of a bond or CH2; Qa, Qb, and Qc are each members independently selected from the group consisting of N, S, O and C(Rq) wherein each Rq is independently selected from the group consisting of H, C1-8 alkyl, halo and phenyl, and the ring having Qa, Qb, Qc and Y as ring vertices is a five-membered ring having two double bonds; and Y is selected from the group consisting of C and N.

Abstract: Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.

Abstract: Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.

Abstract: A process for preparing and purifying a compound of Formula I is provided: or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each Ra is independently selected from the group consisting of (C3-C8)cycloalkyl, (C1-C4)haloalkyl, halogen, —OH, —OR1, —SH, —SR1, —S(O)R1, —S(O)2R1, —SO2NH2, —C(O)NH2, —C(O)NHR1, —C(O)N(R1)2, —C(O)R1, —C(O)H, —CO2R1, —NO2, —NH2, —NHR1, —N(R1)2, wherein each R1 is independently (C1-C8)alkyl; L is a linking group selected from the group consisting of a bond or CH2; Qa, Qb, and Qc are each members independently selected from the group consisting of N, S, O and C(Rq) wherein each Rq is independently selected from the group consisting of H, C1-8 alkyl, halo and phenyl, and the ring having Qa, Qb, Qc and Y as ring vertices is a five-membered ring having two double bonds; and Y is selected from the group consisting of C and N.

Abstract: A process for preparing and purifying a compound of Formula I is provided: or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each Ra is independently selected from the group consisting of (C3-C8)cycloalkyl, (C1-C4)haloalkyl, halogen, —OH, —OR1, —SH, —SR1, —S(O)R1, —S(O)2R1, —SO2NH2, —C(O)NH2, —C(O)NHR1, —C(O)N(R1)2, —C(O)R1, —C(O)H, —CO2R1, —NO2, —NH2, —NHR1, —N(R1)2, wherein each R1 is independently (C1-C8)alkyl; L is a linking group selected from the group consisting of a bond or CH2; Qa, Qb, and Qc are each members independently selected from the group consisting of N, S, O and C(Rq) wherein each Rq is independently selected from the group consisting of H, C1-8 alkyl, halo and phenyl, and the ring having Qa, Qb, Qc and Y as ring vertices is a five-membered ring having two double bonds; and Y is selected from the group consisting of C and N.

Abstract: Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.

Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to fill-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.